Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) — Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to…
Top Pentagon officials have expressed their intention to hold off on releasing an internal report into the attack on a school in southern Iran until after the US midterm elections at the earliest…
(RTTNews) - The Canadian market may open higher on Thursday, tracking firm precious metals and oil prices. However, a sell-off in global tech stocks amid concerns over returns on AI-related…
